SPY—QQQ707.87−0.27%BTC/USD—DIA518.00−0.21%GLD381.40−0.16%TLT80.06+0.01%
Benzinga

Biotech

Ascentage Pharma Stock Could More Than Double: Analyst
Ascentage Pharma Stock Could More Than Double: Analyst
Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow
Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow
Eli Lilly's GLP-1 Pill Wins Key European Backing for Obesity and Diabetes
Eli Lilly's GLP-1 Pill Wins Key European Backing for Obesity and Diabetes
Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow
Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow
Eli Lilly's GLP-1 Pill Wins Key European Backing for Obesity and Diabetes
Eli Lilly's GLP-1 Pill Wins Key European Backing for Obesity and Diabetes
UCB Scores FDA Win With First-Of-Its-Kind Daily Autoinjector for Rare Muscle Disorder
UCB Scores FDA Win With First-Of-Its-Kind Daily Autoinjector for Rare Muscle Disorder
Roche Secures FDA Approval for First At-Home Thyroid Eye Disease Therapy
Roche Secures FDA Approval for First At-Home Thyroid Eye Disease Therapy

Biotech Recent News

Recursion Pharmaceuticals (RXRX) Stock is Trending After Hours: Here’s What You Should Know
Recursion Pharmaceuticals (RXRX) Stock is Trending After Hours: Here’s What You Should Know
Recursion Pharmaceuticals shares rise 0.24% after hours following a $200 million stock offering and a $10 million Sanofi milestone payment.
Krystal Biotech Reports Over 80% Lesion Reduction in Rare Skin Cancer Trial
Krystal Biotech Reports Over 80% Lesion Reduction in Rare Skin Cancer Trial
Krystal Biotech reports clinical updates for KB113, showing over an 80% reduction in basal cell carcinoma lesions in Gorlin syndrome.
Eli Lilly Says New Drug Drives Comprehensive Disease Control in Ulcerative Colitis Patients
Eli Lilly Says New Drug Drives Comprehensive Disease Control in Ulcerative Colitis Patients
New data show Eli Lilly's Omvoh helps ulcerative colitis and Crohn's disease patients achieve long-term, comprehensive disease control.
Vanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary Endpoint
Vanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary Endpoint
Vanda Pharmaceuticals announced its Phase 3 trial for VQW-765 failed to meet primary endpoints for treating acute social anxiety disorder.
Why Is ImmunityBio Stock Gaining Wednesday?
Why Is ImmunityBio Stock Gaining Wednesday?
ImmunityBio (IBRX) stock jumps over 5% following FDA expanded approval for Anktiva in NMIBC bladder cancer treatment. Get details.
Eton Pharmaceuticals Lands Exclusive US Rights To Aquestive's Seizure Rescue Drug
Eton Pharmaceuticals Lands Exclusive US Rights To Aquestive's Seizure Rescue Drug
Eton Pharmaceuticals licenses Aquestive’s LIBERVANT buccal film for U.S. seizure cluster treatment, with launch set for April 2027.
Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments
Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments
Vir Biotechnology and Gilead collaborate on novel T-cell engagers for solid tumors in a deal worth up to $1.87 billion, plus royalties.
What's Going On With Entrada Therapeutics Stock Wednesday?
What's Going On With Entrada Therapeutics Stock Wednesday?
TRDA stock fell over 15% after Entrada Therapeutics announced initial Phase 1/2 ELEVATE-45-201 study results for ENTR-601-45.
Generate Biomedicines Lands Major AI Drug Partnership to Target Booming Obesity Market
Generate Biomedicines Lands Major AI Drug Partnership to Target Booming Obesity Market
Generate Biomedicines & Zealand Pharma team up to develop AI-engineered protein therapies for obesity & metabolic diseases.
What’s Going On With Biomea Fusion (BMEA) Stock After Hours?
What’s Going On With Biomea Fusion (BMEA) Stock After Hours?
Biomea Fusion reports Phase 1 BMF-650 results, with weight reduction and safety data from its oral GLP-1 drug trial.
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved